Novel pharmacological strategies for motor complications in Parkinson's disease.

about

Sigma receptors [σRs]: biology in normal and diseased states Neurotransmission in Parkinson's disease: beyond dopamine.Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases.

P2860

Q37000551-6FC74ED9-B516-4438-90C5-2653A62130E4 Q37668684-C14A9655-83DB-45E1-B0D6-E606EC1513F8 Q44925523-0F03DA0B-5550-446A-9B26-CC1CAD0B8EF1 Q50973291-3EDED895-2F8A-462C-B0FA-9A96F8711D5E

P2860

Novel pharmacological strategies for motor complications in Parkinson's disease.

Item

http://www.wikidata.org/entity/Q36120761

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Novel pharmacological strategies for motor complications in Parkinson's disease.

@ast

Novel pharmacological strategies for motor complications in Parkinson's disease.

@en

type

Item

label

Novel pharmacological strategies for motor complications in Parkinson's disease.

@ast

Novel pharmacological strategies for motor complications in Parkinson's disease.

@en

prefLabel

Novel pharmacological strategies for motor complications in Parkinson's disease.

@ast

Novel pharmacological strategies for motor complications in Parkinson's disease.

@en

P1476

Novel pharmacological strategies for motor complications in Parkinson's disease.

@en

P2093

Spiros Konitsiotis

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist

A controlled trial of rotigotine monotherapy in early Parkinson's disease

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease

Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys

Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease

AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys

Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease

Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys.

P304

377-392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.14.4.377

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15882115

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

Novel pharmacological strategies for motor complications in Parkinson's disease.

about

P2860

P2860

Novel pharmacological strategies for motor complications in Parkinson's disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921